NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO
Background
The exercise period for the warrants of series TO3 took place from
In total, 42,269,834 warrants of series TO3 were exercised for subscription of 42,269,834 series B shares, meaning that approximately 90.4 percent of all outstanding warrants of series TO3 were exercised for subscription of series B shares.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.
Number of shares, share capital and dilution
Through the exercise of the warrants of series TO3, the number of shares in Pharmacolog increases by 42,269,834 series B shares, from 66,250,342 to 108,520,176. The share capital will increase by
For existing shareholders who did not exercise any warrants of series TO3, the dilution amounts to approximately 39.0 percent based on the number of shares following exercise of the warrants of series TO3.
Advisors
This disclosure contains information that Pharmacolog is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on
For more information contact:
Email: lars.gusch@pharmacolog.com
Phone: +46 70-223 97 72
About Pharmacolog
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog's products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by
Further information regarding the company is available at https://pharmacolog.com/.
The company's Certified Adviser is
Important information
The publication, announcement, or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions under law, and individuals in jurisdictions where this press release has been published or distributed should inform themselves about and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each respective jurisdiction. This press release does not constitute an offer to, or an invitation to, acquire or subscribe for any securities in Pharmacolog in any jurisdiction, neither from Pharmacolog nor from any other party.
This press release does not constitute an offer to sell or an invitation to acquire or subscribe for securities in
https://news.cision.com/pharmacolog/r/warrants-of-series-to3-were-subscribed-to-approximately-90-4-percent-and-pharmacolog-receives-approx,c3936382
https://mb.cision.com/Main/12317/3936382/2630926.pdf
https://news.cision.com/pharmacolog/i/pharmacolog-news-500x388px-100,c3271773
(c) 2024 Cision. All rights reserved., source